- Home
- ACHR vs ELVN Comparison
ACHR vs ELVN Comparison
Compare ACHR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- ELVN
- Stock Information
- Founded
- ACHR 2018
- ELVN 2016
- Country
- ACHR United States
- ELVN United States
- Employees
- ACHR N/A
- ELVN N/A
- Industry
- ACHR Aerospace
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ACHR Industrials
- ELVN Health Care
- Exchange
- ACHR Nasdaq
- ELVN Nasdaq
- Market Cap
- ACHR 1.3B
- ELVN 1.1B
- IPO Year
- ACHR N/A
- ELVN 2020
- Fundamental
- Price
- ACHR $11.33
- ELVN $22.71
- Analyst Decision
- ACHR Strong Buy
- ELVN Strong Buy
- Analyst Count
- ACHR 8
- ELVN 5
- Target Price
- ACHR $10.63
- ELVN $37.80
- AVG Volume (30 Days)
- ACHR 55.3M
- ELVN 187.5K
- Earning Date
- ACHR 11-07-2024
- ELVN 11-13-2024
- Dividend Yield
- ACHR N/A
- ELVN N/A
- EPS Growth
- ACHR N/A
- ELVN N/A
- EPS
- ACHR N/A
- ELVN N/A
- Revenue
- ACHR N/A
- ELVN N/A
- Revenue This Year
- ACHR N/A
- ELVN N/A
- Revenue Next Year
- ACHR $2,632.29
- ELVN N/A
- P/E Ratio
- ACHR N/A
- ELVN N/A
- Revenue Growth
- ACHR N/A
- ELVN N/A
- 52 Week Low
- ACHR $2.82
- ELVN $10.90
- 52 Week High
- ACHR $11.36
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- ACHR 73.49
- ELVN 41.94
- Support Level
- ACHR $9.10
- ELVN $21.43
- Resistance Level
- ACHR $10.58
- ELVN $24.42
- Average True Range (ATR)
- ACHR 1.12
- ELVN 1.63
- MACD
- ACHR 0.18
- ELVN 0.02
- Stochastic Oscillator
- ACHR 99.22
- ELVN 28.34
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.